Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Flavia Impronta"'
Autor:
Simona Moffa, Teresa Mezza, Pietro Manuel Ferraro, Gianfranco Di Giuseppe, Chiara M. A. Cefalo, Francesca Cinti, Flavia Impronta, Umberto Capece, Gea Ciccarelli, Andrea Mari, Alfredo Pontecorvi, Andrea Giaccari
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
BackgroundAnti-PCSK9 monoclonal antibodies are effective in reducing LDL-C and cardiovascular events by neutralizing circulating PCSK9. PCSK9, however, is also expressed in tissues, including the pancreas, and studies on PCSK9 KO mice have shown impa
Externí odkaz:
https://doaj.org/article/d041aae5035c4b3bbd289cbe18497dc1
Autor:
Chiara Maria Assunta Cefalo, Francesca Cinti, Simona Moffa, Flavia Impronta, Gian Pio Sorice, Teresa Mezza, Alfredo Pontecorvi, Andrea Giaccari
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-14 (2019)
Abstract Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant exc
Externí odkaz:
https://doaj.org/article/70136c1bc5c541a7b9f40975e58adce4
Autor:
Simona Moffa, Teresa Mezza, Chiara M. A. Cefalo, Francesca Cinti, Flavia Impronta, Gian Pio Sorice, Antonio Santoro, Gianfranco Di Giuseppe, Alfredo Pontecorvi, Andrea Giaccari
Publikováno v:
Mediators of Inflammation, Vol 2019 (2019)
Diabetes is not a single and homogeneous disease, but a cluster of metabolic diseases characterized by the common feature of hyperglycemia. The pathogenesis of type 1 diabetes (T1D) and type 2 diabetes (T2D) (and all other intermediate forms of diabe
Externí odkaz:
https://doaj.org/article/4b96bd863b77465ab661349471e19d03
Autor:
Daniela Fignani, Gianfranco Di Giuseppe, Noemi Brusco, Simona Moffa, Laura Nigi, Andrea Giaccari, Chiara Maria Assunta Cefalo, Francesca Cinti, Flavia Impronta, Teresa Mezza, Guido Sebastiani, Giada Licata, Umberto Capece, Andrea Mari, Giuseppina Emanuela Grieco, Francesco Dotta
Publikováno v:
Diabetes. 70
Proinsulin (PI) processing is altered in beta-cells during T2D progression. However, the molecular mechanisms driving such alterations are not fully characterized neither their occurrence were correlated with patients’ metabolic profile. To fill th
Autor:
Gian Pio Sorice, Chiara Maria Assunta Cefalo, Alfredo Pontecorvi, Francesca Cinti, Teresa Mezza, Flavia Impronta, Simona Moffa, Andrea Giaccari
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-14 (2019)
Cardiovascular Diabetology
Cardiovascular Diabetology
Sotagliflozin is a dual sodium–glucose co-transporter-2 and 1 (SGLT2/1) inhibitor for the treatment of both type 1 (T1D) and type 2 diabetes (T2D). Sotagliflozin inhibits renal sodium–glucose co-transporter 2 (determining significant excretion of
Autor:
Lorella Marselli, Andrea Mari, Saverio Cinti, Sergio Alfieri, Giuseppe Quero, Alfredo Pontecorvi, Flavia Impronta, Simona Moffa, Mara Suleiman, Teresa Mezza, Andrea Giaccari, Francesca Cinti, Gian P. Sorice, Piero Marchetti, Chiara Maria Assunta Cefalo, Ilenia Severi
Aims/hypothesis Type 2 diabetes (T2D) is characterized by a progressive loss of beta-cell function, and the “disappearance” of beta-cells in T2D may also be caused by the process of beta -cell dedifferentiation. Since noradrenergic innervation in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f82093d5913c0e5900f449d5827a473
http://hdl.handle.net/10807/169262
http://hdl.handle.net/10807/169262
Autor:
Gea Ciccarelli, Francesca Cinti, Andrea Giaccari, Chiara M. Cefalo, Gianfranco Di Giuseppe, Simona Moffa, Flavia Impronta, Alfredo Pontecorvi, Umberto Capece, Teresa Mezza
INTRODUCTION Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder whose rising incidence suggests the epidemic proportions of the disease. Impaired fasting glucose (IFG) and Impaired Glucose Tolerance (IGT) - alone or combined - represent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38934f37da3ed1553ce87b5ed86b5c4
http://hdl.handle.net/10807/183578
http://hdl.handle.net/10807/183578
Autor:
Pietro Manuel Ferraro, Francesca Cinti, Giuseppe Quero, Simona Moffa, Andrea Mari, Teresa Mezza, Gianfranco Di Giuseppe, Andrea Giaccari, Chiara Maria Assunta Cefalo, Flavia Impronta, Umberto Capece, Alfredo Pontecorvi, Sergio Alfieri
Publikováno v:
J Clin Invest
BACKGROUNDThe appearance of hyperglycemia is due to insulin resistance, functional deficits in the secretion of insulin, and a reduction of β cell mass. There is a long-standing debate as to the relative contribution of these factors to clinically m
Autor:
Umberto Capece, Teresa Mezza, Simona Moffa, Andrea Giaccari, Andrea Mari, Francesca Cinti, Gian Pio Sorice, Chiara Maria Assunta Cefalo, Flavia Impronta
Publikováno v:
Diabetes. 69
PCSK9 inhibitors are monoclonal antibodies effective in reducing LDL-C and cardiovascular events by neutralizing circulating PCSK9. Since PCSK9 is also expressed in other organs, including pancreas, studies on PCSK9 KO mice, have shown impaired insul
Autor:
Giuseppe Quero, Sergio Alfieri, Umberto Capece, Andrea Mari, Simona Moffa, Andrea Giaccari, Flavia Impronta, Gianfranco Di Giuseppe, Chiara Maria Assunta Cefalo, Francesca Cinti, Pietro Manuel Ferraro, Teresa Mezza
Publikováno v:
Diabetes. 69
β-cell functional defects temporally anticipate (and eventually cause) the subsequent development of hyperglycemia, whereas a significant reduction (∼50%) of beta-cell mass is observed at diagnosis of T2D. To further investigate the relative role